Karus Therapeutics Appoints Dr Stephen Shuttleworth as Chairman of Scientific Advisory Board


Oxfordshire, UK, 17 September 2019 – Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, today announced that Dr Stephen Shuttleworth will become Chairman of its Scientific Advisory Board with immediate effect.

After almost 12 years with Karus, the Company’s Founding Scientist and CSO (and latterly joint COO/CSO) and Executive Director, Dr Stephen Shuttleworth, has elected to increase his time commitment to his Entrepreneur-in-Residence position at Samsara BioCapital LLC, a venture capital firm in Palo Alto, USA and Samsara affiliates.

The Board is grateful for the contributions Steve has made in building the company since 2008, and, in particular for the research and preclinical development of KA2237 and KA2507 – both now in clinical trials in cancer patients. The Board has asked Steve to become Chair of Karus’s Scientific Advisory Board and remain an adviser to the company.


For more information, please contact:

Instinctif Partners
Sue Charles / Dr Christelle Kerouedan / Dr Katie Duffell
Tel: +44 (0)20 7457 2013
Email: karus@instinctif.com

Notes to Editors

About Karus Therapeutics
Karus Therapeutics, based in Oxfordshire, UK, is a clinical-stage biopharmaceutical company developing precision medicines for cancer. The Company’s orally-active, small molecule drugs combine targeted and immunotherapeutic mechanisms of action for the treatment of cancer patients with clear unmet medical need and limited treatment options. Karus has two small molecule clinical candidates in Phase I studies, KA2507 and KA2237. The Company is privately-held and is supported by a world-leading syndicate of life science investors from the US and Europe: SV Health Investors, New Leaf Ventures, Novo A/S and IP Group. For further information please visit: www.karustherapeutics.com